证券代码：300595 证券简称：欧普康视 公告编号：2024-079 欧普康视科技股份有限公司 关于控股子公司为其子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保概述 欧普康视科技股份有限公司（以下简称"公司"）全资子公司欧普康视投资有 限公司的控股子公司莱州同明中西医结合医院有限公司（以下简称"莱州同明医院 "）的全资子公司莱州同辉医疗器械有限公司（以下简称"莱州同辉"）拟向山东 莱州农村商业银行股份有限公司文昌支行申请总额不超过人民币400万元的授信额 度，授信期限3年，莱州同明医院同意为莱州同辉向上述银行申请总额不超过人民 币400万元融资事项提供连带责任保证担保。同时烟台融资担保集团有限公司为莱州 同辉向上述授信额度融资事项提供连带责任保证担保，莱州同明医院就烟台融资担 保集团有限公司担保事项提供反担保。 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》等相关规定，本次担保事项属于上市公司控股子公司为上市公司合并报表 范围内的法人提供担保，控股子公司莱州同明医院已履行内部审批程序，无需 提交公 ...

股票简称：欧普康视 证券代码：300595 公告编号：2024-078 欧普康视科技股份有限公司 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押数 | 所持 | 司总 | 是否 | 为补 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | 售股 | 押 | | | | | | | 致行动人 | | （%） | (%) | | | | 办理解除 | 广发证券 | 补充 | | | | 262,000 | 0.21 | 0.03 | 否 | 是 | 2024/8/21 | 质押登记 手续之日 | 股份有限 公司 | 质押 | | | | 79,000 | 0.06 | 0.01 | 否 | 是 | 2024/8/21 | 办理解除 质押登记 | 招商证券 股 ...

Investment Rating - The report maintains a "Hold" rating for the company [3][4]. Core Views - The company is experiencing pressure on its performance, with a focus on waiting for a turning point in its business [4]. - The revenue for H1 2024 reached 880 million yuan, representing a year-on-year increase of 13.2%, while the net profit attributable to the parent company was 320 million yuan, up 4.4% year-on-year [4]. - The company is expanding its optical service terminals, with over 470 locations, aiming to enhance product and service revenue [4]. Summary by Relevant Sections Earnings Forecast and Investment Suggestions - EPS is projected to be 0.91 yuan for 2024, 1.06 yuan for 2025, and 1.23 yuan for 2026 [2][5]. Financial Data - Total shares outstanding: 899.7 million - Market capitalization: 12.479 billion yuan - Total assets: 5.561 billion yuan - Net asset per share: 4.98 yuan [2]. Performance Summary - H1 2024 revenue breakdown: - Rigid contact lens revenue: 370 million yuan (down 2.7%) - Care product revenue: 120 million yuan (down 3.8%) - Ordinary frame glasses and other revenue: 160 million yuan (up 44.3%) [4]. - H1 2024 gross margin: 73.8% (down 1.8 percentage points year-on-year) [4]. Expense Analysis - Sales expense ratio: 24.8% (up 3.4 percentage points year-on-year) - Management expense ratio: 4.5% (down 1.3 percentage points year-on-year) - R&D expense ratio: 2.3% (down 0.1 percentage points year-on-year) [4]. Market Position and Growth Potential - The company is actively expanding its optical service terminals, indicating potential for future growth in both product and service revenues [4].

Group 1: Company Performance - The company reported a revenue increase of over 25% in its optical service business, which now accounts for more than 52% of total revenue [4] - The sales of frame glasses and other optical products reached 161 million CNY, reflecting a growth of 44% [5] - The company has added over 470 optical service terminals, with terminal business revenue also growing over 25% [4] Group 2: Product Development and Market Strategy - The company is currently conducting Phase III clinical trials for low-concentration atropine eye drops, with enrollment ongoing [3] - The sales of orthokeratology lenses have shown fluctuations, with a weaker second quarter compared to the first [3] - The company remains optimistic about the long-term prospects of orthokeratology lenses, citing unique benefits such as allowing users to not wear glasses during the day [3] Group 3: Competitive Landscape - The orthokeratology lens market faces challenges due to high-end consumer fatigue and increased competition from various myopia control products [5] - Despite current growth challenges, the company believes that orthokeratology lenses will remain a preferred choice due to their proven effectiveness and user satisfaction [5] Group 4: Investor Relations and Communication - The company held an online investor meeting to address questions regarding its semi-annual report and to understand investor concerns [6] - The management team emphasized their commitment to a comprehensive optical product and service strategy, adapting to macroeconomic conditions [6]

人民币(元) 成交金额(百万元) 15.00 17.00 19.00 21.00 23.00 25.00 27.00 29.00 0 100 200 300 400 500 230815231012231209240205240403240531240728 成交金额 欧普康视 沪深300 公司基本情况（人民币） 项目 2022 2023 2024E 2025E 2026E 营业收入(百万元) 1,525 1,737 2,031 2,346 2,686 营业收入增长率 17.78% 13.89% 16.90% 15.53% 14.46% 归母净利润(百万元) 624 667 757 855 959 归母净利润增长率 12.44% 6.87% 13.63% 12.85% 12.20% 摊薄每股收益(元) 0.697 0.743 0.844 0.953 1.069 每股经营性现金流净额 0.65 0.71 1.78 1.05 1.17 ROE(归属母公司)(摊薄) 14.74% 15.32% 15.36% 15.25% 15.02% P/E 51.22 30.39 18.97 16.81 14.99 P/B 7. ...

Investment Rating - The report maintains a cautious buy rating for the company [5][7]. Core Views - The company's performance for H1 2024 is in line with expectations, achieving revenue of 883 million yuan (+13.21%) and a net profit of 324 million yuan (+4.42%) [5]. - The company has adjusted its EPS forecasts for 2024-2026 to 0.80, 0.92, and 1.06 yuan respectively, down from previous estimates of 0.86, 0.99, and 1.14 yuan [5]. - The target price for 2024 is set at 17.60 yuan, based on a PE ratio of 22x [5]. Revenue Breakdown - Revenue from the company's core product,角塑, was 373 million yuan (-3%), impacted by weak high-end consumption and increased competition [5]. - Nursing products generated 117 million yuan (-4%), with a notable increase in gross margin by 6.66 percentage points to 60.65% due to strong promotion of self-produced nursing products [5]. - Revenue from other optical products and technical services reached 161 million yuan (+44.28%), driven by strong growth in non-focus frame glasses [5]. - Medical services revenue was 191 million yuan (+46%), attributed to rapid growth from newly consolidated hospitals, although gross margin decreased by 8.81 percentage points to 64.97% [5]. Cost and Profitability - The company's gross margin for H1 2024 was 73.77% (-1.8 percentage points), primarily due to a decrease in the proportion of high-margin角塑 revenue [5]. - The increase in sales and marketing expenses has temporarily affected the net profit margin, with sales expenses rising due to the addition of sales and technical support personnel [5]. Product Development - The company has a rich pipeline of products under development, including new generation角塑 materials, multifocal soft lenses, lubricants, nursing liquids, and eye comfort devices, indicating significant growth potential [5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's H1 2024 performance met expectations, with revenue of 883 million yuan (+13.21% YoY) and net profit attributable to the parent company of 324 million yuan (+4.42% YoY) [3] - OK lens sales declined slightly due to weak high-end consumption, with revenue of 373 million yuan (-3% YoY) and gross margin of 88.32% (-1.13pct) [3] - The company's R&D pipeline is progressing well, with multiple new products in development and clinical trials [3] Financial Performance - Revenue is expected to grow from 1,737 million yuan in 2023 to 2,752 million yuan in 2026, with a CAGR of 14.45% [2] - Net profit attributable to the parent company is forecasted to increase from 666.60 million yuan in 2023 to 943.01 million yuan in 2026, with a CAGR of 12.24% [2] - EPS is projected to rise from 0.74 yuan in 2023 to 1.05 yuan in 2026 [2] Regional Performance - Revenue growth exceeded 10% in the Northeast, East China, and North China regions, driven by contributions from newly consolidated medical institutions [3] - The company has established partnerships with over 2,000 terminal outlets and owns or holds stakes in more than 470 optometry service terminals [3] Product Development - The company is expanding production of its self-developed lens replacement materials, with the second-generation materials for high-oxygen permeable orthokeratology lenses and scleral lenses already submitted for registration [3] - Multi-focus soft contact lenses are in multi-center clinical trials, and new specifications for care products have been launched to meet offline and online demand [3] - The company has made breakthroughs in the development of hydrogen peroxide disinfectant and is researching medical-grade hydrogen peroxide care solutions [3] Valuation - The company's current P/E ratio is 21.56x, expected to decrease to 15.24x by 2026 [2] - The P/B ratio is 3.30x, projected to decline to 2.12x by 2026 [9] - ROE is forecasted to remain stable around 13.88% from 2024 to 2026 [9]

股票简称：欧普康视 证券代码：300595 公告编号：2024-070 欧普康视科技股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏 一、监事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届监事会第十 一次会议，于 2024 年 8 月 6 日以专人送达、即时通讯等方式发出会议通知。 二、监事会会议审议情况 1 （二）会议于 2024 年 8 月 15 日以现场形式召开。 （三）本次会议应参与表决监事 3 人，实际参与表决监事 3 人。 （四）会议由监事会主席孙永建先生主持。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 (三) 以 3 票赞成，0 票反对，0 票弃权审议通过《关于调整 2023 年限制性 股票激励计划首次授予股份回购价格的议案》 经审核，监事会同意：对 2023 年限制性股票激励计划首次授予股份（已授 予但尚未解除限售）的回购价格进行调整，本次调整后首次授予股份回购价格为 14.927 元/股。 (四)以 3 票赞成，0 票反对，0 票弃权审议通过《关于拟回购注 ...

附件： 欧普康视科技股份有限公司 2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：欧普康视科技股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公 | 上市公司核算的 | 2024年初占用资 | 2024半年度占用 | 2024半年度占用 | 2024半年度偿还 | 2024半年度末占 | | | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | 金余额 | 累计发生金额 (不含利息) | 资金的利息(如 有) | 累计发生金额 | 用资金余额 | 占用形成原因 | 占用性质 | | | | | | | | | | - | | 非经营性占用 | | 控股股东、实际控制人 及其附属企业 | | | | | | | | - | | 非经营性占用 | | | | | | | | | | - | | 非经营性占用 | | 小计 | — | — | — | - | | - | - - | ...

关于募集资金 2024 年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作（2023 年 12 月修订）》等监管要求及公司《募集资金管理 制度》的规定，欧普康视科技股份有限公司（以下简称"公司"）编制了 2024 年半年度募集资金存放与使用情况的专项报告，具体情况如下： 证券代码：300595 证券简称：欧普康视 公告编号：2024-074 欧普康视科技股份有限公司 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 公司本次向特定对象发行股票事项经中国证券监督管理委员会《关于同意欧 普康视科技股份有限公司向特定对象发行股票注册的批复》（证监许可 [2021]3405 号）同意注册。公司本次向特定对象发行人民币普通股（A 股） 42,594,826 股，每股面值 1 元，每股发行价格人民币 35.29 元，募集资金总额 为人民币 1,503,171,40 ...